Meta-analysis of 64 placebo-controlled approval trials of biologic and targeted synthetic DMARDs in rheumatoid arthritis found comparable overall adverse and serious adverse event rates, but differing profiles by organ class and adverse events of special interest.
Meta-analysisn = 64 trials
Konzett et al. Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials